Precision Medicine: PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer VL

Clinical Trial Equity in Radionuclide Treatment for Prostate Cancer - Joseph Osborne

Details
Phillip Koo is joined by Joseph Osborne to provide a nuclear radiologist's perspective on the equity in prostate cancer clinical trials. Dr. Osborne focuses his talk on three different aspects of clinical trial equity for prostate cancer: Progress, Evolution, and Goals. He also details the Rad Health Equity Lab, created at Weill Cornell to improve access to radiology and bring awareness to health...

Clinical Implementation of Pluvicto™ (177Lu-PSMA-617) - Michael Morris

Details
Michael Morris joins Alicia Morgans to discuss the clinical implementation of Pluvicto™ (177Lu-PSMA-617) in a way that ensures equity to all patients, regardless of the many factors that could disrupt access. They discuss equity of distribution to all those patients who need it and the availability of PSMA PET scans. Biographies: Michael Morris, MD, Medical Oncologist Clinical Director, Genitourin...

Pluvicto™ (177Lu-PSMA-617) Indications for Clinical Use in PSMA Positive Metastatic Castration-Resistant Prostate Cancer mCRPC - Oliver Sartor

Details
Oliver Sartor joins Phillip Koo to discuss the United State FDA approval of Pluvicto™ (177Lu-PSMA-617) as the first targeted radioligand therapy for the treatment of PSMA positive metastatic castration-resistant prostate cancer (mCRPC). They discuss currently enrolling in clinical trials with Pluvicto in the pre-chemotherapy treated mCRPC patient population. They look further into the future discu...

Pluvicto The First Targeted Radioligand Therapy for Treatment of Metastatic Castration-Resistant Prostate Cancer FDA Approved - Charles Ryan and Alicia Morgans

Details
Drs Charles Ryan and Alicia Morgans discuss the approval of Pluvicto TM (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617). Pluvicto was approved based on the pivotal Phase III VISION trial which evaluated men who had post androgen receptor pathway inhibitor therapy and post docetaxel or docetaxel and cabazitaxel chemotherapy, who were randomized to a protocol-defined...

Radionuclide Targeted Treatment in Progressing Metastatic Prostate Cancer - Michael Hofman

Details
PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer Module 1 15 minutes: Radionuclide Targeted Treatment in Progressing Metastatic Prostate Cancer - Presented by Michael Hofman, MBBS (Hons), FRACP, FAANMS, FICIS 20 minutes: Discussion Moderators Phillip Koo, MD, Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS. Biographies: Professor Michael Hofman, MBBS (Hons), FRACP, FAANMS, FICIS...

PSMA-PET Imaging in Prostate Cancer & PSMA as a Therapeutic Target in Prostate Cancers - Thomas Hope and Johannas Czernin

Details
PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer Module 2 12 minutes: PSMA-PET Diagnostic Imaging in Prostate Cancer - Presented by Thomas Hope, MD Module 3 16 minutes: PSMA as a Therapeutic Target in Progressing Prostate Cancer - Presented by Johannes Czernin, MD 22 minutes: Discussion moderators Phillip Koo, MD, Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS. Biographies: Joh...

PSMA-directed Therapy - Scott Tagawa and Michael Morris

Details
PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer Module 4 10 minutes: Treatment considerations following 177Lu-PSMA - Presented by Scott Tagawa, MD, MS, FACP 17 minutes: PSMA Imaging: A Necessary Gateway for PSMA-Directed Therapy? - Presented by Michael Morris, MD 24 minutes: Discussion Moderators Phillip Koo, MD, Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS. Biographies: Sco...

PSMA Targeted Radiopharmaceuticals in Prostate Cancer: Pivotal Phase III VISION Trial - Oliver Sartor

Details
PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer. Module 5 12 minutes: PSMA Targeted Radiopharmaceuticals in Prostate Cancer: Introducing the Pivotal Phase III VISION Trial - Presented by Oliver Sartor, MD 11 minutes: Discussion Moderators Phillip J. Koo, MD, Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS Biographies: Oliver Sartor, M.D. C.E. and Bernadine Laborde Professor of...

Precision Medicine: RadioIsotopes Targeted Therapies in Cancer - Stefano Fanti

Details
PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer Module 6 14 minutes: Precision Medicine: RadioIsotopes Targeted Therapies in Cancer - Presented by Stefano Fanti, MD 15 minutes: Discussion Moderators Phillip J. Koo, MD, Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS. Biographies: Stefano Fanti, MD Nuclear Medicine Physician, Director of the Nuclear Medicine Division and PET Uni...

Academic and Community Practice Perspectives on Integrating PSMA Lutetium in the Clinic: Lessons Learned from Radium-223 Experience - Oliver Sartor and Nicholas Vogelzang

Details
PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer Module 7 9 minutes: Academic Practice Perspectives on Integrating PSMA Lu-177 into Clinical Practice: Lessons Learned from Radium-223 and More - Presented by Oliver Sartor, MD. 6 minutes: Practice Patterns in a Community Medical Oncology Applied to Lutetium: Parallels between lutetium and operationalizing radium-223 - Presented by N...
email news signup